Abstract
Background: Prader-Willi Syndrome (PWS) is a rare genetic disorder associated with developmental delay, obesity, and neuropsychiatric comorbidities. Bifidobacterium animalis subsp. lactis has demonstrated anti-obesity and anti-inflammatory effects in previous studies. Aim: To evaluate the effects of Bifidobacterium animalis subsp. lactis probiotics supplementation on anthropometric growth, behavioral symptoms, and gut microbiome composition in patients with PWS. Methods: We conducted a 12-week, randomized, double-blind, placebo-controlled trial in 68 patients with PWS aged 11 months-16 years. Participants were randomly assigned to receive daily B. lactis-11 probiotics ($6 \times 10^{10}$ CFUs) or a placebo. Weight, height, and various behavioral scales (ASQ-3, ABC, SRS-2, CGI-I) were compared at baseline, 6, and 12 weeks. Gut microbiome data were analyzed via 16S rRNA sequencing. Results: A significant increase in height (mean difference = 2.68 cm, $P < 0.05$) and improvement in CGI-I ($P < 0.05$) were observed in the probiotics group. No significant changes in weight or psychological measures were found. Probiotic treatment altered microbiome composition and increased the abundance of antioxidant production-related genes. Conclusions: B. lactis probiotics show therapeutic potential for PWS, particularly regarding linear growth and clinical status.
Introduction
Prader-Willi Syndrome (PWS) is a complex multisystem genetic disorder characterized by early-life hypotonia and feeding difficulties, followed by a transition to hyperphagia and a high risk of morbid obesity. Beyond metabolic challenges, PWS patients often experience developmental delays and neuropsychiatric issues. While Growth Hormone (GH) therapy is a standard intervention for linear growth, it is invasive and costly. Recent evidence suggests that gut dysbiosis—an imbalance in the microbial community—may contribute to the metabolic and inflammatory phenotype of PWS. This study investigates the potential of Bifidobacterium animalis subsp. lactis (BL-11) to modulate the gut-brain axis and improve clinical outcomes in pediatric PWS patients.
Methods
The researchers conducted a 12-week, randomized, double-blind, placebo-controlled trial involving 68 genetically confirmed PWS patients (mean age 4.2 years). The intervention group ($n=33$) received daily sachets of B. lactis-11 ($6 \times 10^{10}$ CFUs), while the control group ($n=35$) received a maltodextrin placebo. Primary outcomes included age-adjusted z-scores for height and weight, and behavioral assessments using the Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS-2), and Ages and Stages Questionnaires (ASQ-3). Stool samples were collected at 0, 6, and 12 weeks for 16S rRNA gene sequencing (NCBI SRA accession: PRJNA643297).
Key Results
Anthropometric Growth and Clinical Impression
The most significant finding was a marked increase in linear growth. Between weeks 6 and 12, the probiotic group exhibited a significantly greater increase in height compared to the placebo group, with a mean difference of 2.68 cm ($P < 0.05$). Clinicians also noted a significant improvement in the Clinical Global Impression (CGI-I) scale for the probiotic group. Interestingly, no significant changes were observed in weight or BMI z-scores within the 12-week study period.
Microbial Re-tuning and Diversity
Probiotic supplementation successfully altered the gut microbiome landscape. Alpha diversity increased significantly in the probiotic group by week 6. Taxonomic analysis revealed a reduction in "pro-obesity" and "pro-inflammatory" taxa, such as Lachnospiraceae and Ruminococcaceae, alongside an increase in beneficial genera like Lactobacillus.
Functional gene analysis using PICRUSt-2 further indicated an upregulation of genes related to ubiquinone (CoQ10) biosynthesis in the probiotic group. CoQ10 is essential for mitochondrial function and antioxidant defense, suggesting a molecular-level improvement in metabolic health.
Discussion and Limitations
The study demonstrates that B. lactis-11 supplementation can positively influence linear growth and overall clinical status in children with PWS. The increase in height suggests a possible interaction with endogenous growth pathways or improved nutrient absorption. However, the 12-week duration may have been insufficient to capture changes in weight or complex behavioral traits.
Limitations include the wide age range of participants (11 months to 16 years) and the lack of direct measurements for serum growth hormone or IGF-1. Additionally, dietary intake was not strictly controlled. Future research should employ longer follow-up periods and larger, age-stratified cohorts to further elucidate the mechanisms behind these probiotic-induced improvements.
Summary updated